家蚕转基因载体pBacA3EG的构建及其表达

以家蚕Bombyx mori肌动蛋白A3(actin 3)启动子、增强性绿色荧光蛋白(enhanced green fluorescent protein, EGFP)基因及SV40的多聚腺苷酸识别序列为元件,经多次克隆,将其插入到piggyBac转座载体中。经PCR、酶切鉴定及测序表明各元件已按正确的方式插入到piggyBac载体中。将构建好的piggyBac表达载体显微注射到胚盘形成前期的蚕卵中,在胚胎早期发育的第3天,通过体视荧光显微镜检测到蚕卵内发出较强的绿色荧光。结果表明该载体构建正确且能在蚕卵中进行表达。家蚕转基因载体的体外瞬时表达不但是成功进行家蚕转基因所必需的第一步,而且其自身也可以应用于基因的功能研究,为家蚕后基因组研究奠定了基础。     

家蚕转基因技术中若干因素对转基因效率的影响

建立高效、稳定的家蚕Bombyx mori转基因技术对于推进家蚕功能基因组研究, 解决蚕丝产业重大问题以及向非绢丝产业拓展等具有重要意义。本文在已建立的基于piggyBac的家蚕转基因技术基础上, 探索了多个影响转基因效率的因素。结果显示：以家蚕品种大造 (P50) 为供试材料、pBac［GOI］为供体质粒、pHA4PIG为辅助质粒, 以眼睛和神经组织特异启动子3×p3启动的红色荧光蛋白基因DsRed为报告基因, 在蚕卵产下后2～3 h进行注射,综合效果最佳, 孵化率和转化率分别达到62.7%和34.8%;荧光筛选的最佳时期在胚胎发育第5到第8天;在2 000～8 000 bp之间时, 外源片段的长度对转化率并无太大影响。本研究建立的技术体系, 有望为家蚕功能基因研究、品种分子改良和家蚕生物反应器的开发奠定基础, 并为其他鳞翅目昆虫转基因技术的建立提供参考。     

转植酸酶基因家蚕的制作及表达检测

家蚕Bombyx mori丝腺具有高效合成蛋白质的特性,开发在丝腺特异表达外源蛋白质的生物反应器具有重要的意义。本研究利用piggyBac来源的两种载体pPIGA3GFP和pBac{3×P3-EGFPaf},建立了稳定的家蚕转基因技术体系; 然后,利用一株黑曲霉来源的植酸酶基因,构建了在家蚕后部丝腺特异表达的融合表达载体pBac [3×P3-EGFP+ FibLphyADsRed],注射蚕卵后,在53个G1蛾区中检测到3个有荧光蚕的蛾区。经Southern blot和反向PCR验证,转基因表达盒整合到家蚕染色体上。RT-PCR结果显示,植酸酶基因特异性地在后部丝腺表达,其表达模式与家蚕轻链丝素基因一致。结果表明我们成功获得了在后部丝腺特异表达植酸酶融合蛋白的转基因蚕,这为进一步开发家蚕生物反应器,利用转基因蚕生产各种重组蛋白具有积极的促进作用。     

piggyBac转座子介导的转基因叉尾斗鱼的构建

为探讨piggyBac转座子在鱼类动物中应用的可能性,以包含家蚕(Bombyx mori)肌动蛋白3启动子驱动的增强型绿色荧光蛋白(enhance green fluorescent protein,EGFP)基因的piggyBac质粒为载体,以及一个包含piggyBac转座酶的辅助质粒,采用显微注射的方法将其导入叉尾斗鱼(Macropodusopercularis)受精卵中,利用PCR技术证实了piggyBac转座子能够介导EGFP基因进入叉尾斗鱼基因组,并能够稳定遗传到下一代,符合孟德尔遗传规律。EGFP基因遗传到G1代的阳性鱼占交配鱼比率,即外源基因整合率为12.30%。实验证明,piggyBac质粒有可能成为水产动物转基因实验的新型载体。     

多聚唾液酸与多聚唾液酸转移酶

多聚唾液酸（PSA）是一种在神经细胞黏附分子（neural cell adhesion molecule,NCAM）上表达的唾液酸聚合物,在神经发育过程中起重要作用.PSA的聚合程度会影响PSA-NCAM的功能.多聚唾液酸酶主要用于合成PSA-NCAM,两种高度同源的多聚唾液酸转移酶ST8SiaⅡ和ST8SiaⅣ都属于唾液酸转移酶家族.多聚唾液酸转移酶中NCAM的识别域和多聚唾液酸化域是截然不同的,且一些异构酶在NCAM多聚唾液酸化中起明显的负作用.多聚唾液酸酶与很多疾病都有关系,以多聚唾液酸转移酶为标靶设计的药物也将成为神经系统及肿瘤治疗的新型药物.     

重组家蚕病毒表达系统转移载体的构建和β─半乳糖苷酶的表达

本文从中国农科院蚕业研究所提供的我国家蚕核多角体病毒镇江株中获得了多角体蛋白的强启动子,用此启动子构建了家蚕病毒表达系统的转移载体。外源基因能在此启动子控制下在家蚕细胞和虫体中进行高效表达。用此载体我们首先成功地在家蚕虫体中高效表达了β－半乳糖苷酶,表达量达到５８０μｇ／条蚕,从而证实我们构建的载体是可靠的、有效的,可用于家蚕重组病毒表达外源基因的研究。     

特异性检测胰腺组织表达Cre重组酶转基因小鼠的方法

利用组织特异性分子标志物启动子调控Cre重组酶,研制了6种在不同组织中特异性表达Cre重组酶的转基因小鼠.这些转基因小鼠的基因型鉴定均使用设计在Cre基因编码区的通用引物.为了特异性检测胰腺组织表达Cre重组酶的转基因小鼠,在大鼠胰岛素RIP启动子上和Cre基因上设计1对引物进行PCR扩增,并通过凝胶电泳进行分析.PCR结果显示,设计在Cre基因上的通用引物可以从6种不同组织特异性Cre重组酶转基因小鼠基因组DNA中扩增获得480 bp产物;利用本研究设计的特异性引物可以从胰腺组织表达Cre重组酶转基因小鼠基因组DNA中扩增200 bp的目的条带.这一结果表明,利用特异性引物进行PCR反应,可有效地将胰腺组织表达Cre重组酶转基因小鼠与其他多种组织的Cm重组酶转基因小鼠鉴别开来.     

家蚕中肠特异启动子P56的克隆及活性分析

中肠是家蚕的消化器官,也是抵御外界病源入侵的生理屏障。为克隆和鉴定新的家蚕中肠特异启动子,首先利用RT-PCR检测家蚕组织特异表达候选基因Bm P56的表达特性,发现该基因只在中肠组织表达。进一步克隆该基因上游调控序列P56,构建由该序列驱动红色荧光蛋白基因DsRed表达的转基因载体p Bac[P56DsRed SV40,3×P3EGFP],经显微注射和荧光筛选获得转基因家蚕。表达分析显示,报告基因DsRed只在转基因家蚕中肠组织表达,与Bm P56的表达特征一致,说明克隆的上游调控序列P56是有活性的家蚕中肠特异启动子。     

PiggyBac在转基因小鼠制备中的应用

受精卵雄原核裸DNA注射是目前制备转基因小鼠的主要技术,而转基因表达成功率低是这种技术的主要缺点。piggyBac转座子系统已被报道用于制备转基因小鼠,但这一方法是否能够提高转基因的表达成功率尚不清楚。为此,我们利用毛色基因agouti为报告基因,采用piggyBac转座子系统以C57/BL6小鼠为背景进行转基因小鼠的制备。结果表明,将piggyBac转座酶cRNA和转基因载体进行受精卵雄原核共注射后,转基因阳性率为18.4%,转基因表达率为88.89%,显著高于单独进行转基因载体DNA受精卵雄原核注射法。同时,利用agouti基因作为报告基因,可根据毛色变化直接对表达阳性的转基因小鼠进行初步筛选,提高了筛选效率。     

转基因家蚕丝腺组织和转化家蚕培养细胞表达hIGF-I

为实现在家蚕培养细胞和家蚕丝腺组织中表达人胰岛素样生长因子（hIGF-I）基因,以家蚕丝胶基因启动子（Pser-1）驱动hIGF-I基因,构建了带有家蚕杆状病毒ie-1启动子（Pie-1）控制的neo基因表达盒的转基因载体pigA3GFP—hIGF-ie—neo．在可表达转座酶的辅助质粒存在下,分别转染BmN培养细胞,以700～800μg/mL的G418筛选,获得了稳定转化细胞系．Westernblotting分析可检测到hIGF-I的特异性条带,ELISA检测结果显示,hIGF-I在5-100个细胞中的表达水平约7800Pg．通过反向PCR分析表明,在转化细胞中外源DNA可通过随机整合或按照piggyBac特定的靶位点序列TTAA插入细胞基因组．转基因载体pigA3GFP-hIGF—ie-neo通过精子介导法导入蚕卵,利用neo,加基因的双重筛选,经过PCR和点杂交鉴定,获得了2头转基因家蚕．ELISA检测结果显示,在G1代hIGF-I在每克中部丝腺组织中的表达水平为2440Pg左右．     

Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response

Traditional production of therapeutic glycoproteins relies on mammalian cell culture technology. Glycoproteins produced by mammalian cells invariably display N-glycan heterogeneity resulting in a mixture of glycoforms the composition of which varies from production batch to production batch. However, extent and type of N-glycosylation has a profound impact on the therapeutic properties of many commercially relevant therapeutic proteins making control of N-glycosylation an emerging field of high importance. We have employed a combinatorial library approach to generate glycoengineered Pichia pastoris strains capable of displaying defined human-like N-linked glycans at high uniformity. The availability of these strains allows us to elucidate the relationship between specific N-linked glycans and the function of glycoproteins. The aim of this study was to utilize this novel technology platform and produce two human-like N-linked glycoforms of recombinant human lactoferrin (rhLF), sialylated and non-sialylated, and to evaluate the effects of terminal N-glycan structures on in vitro secondary humoral immune responses. Lactoferrin is considered an important first line defense protein involved in protection against various microbial infections. Here, it is established that glycoengineered P. pastoris strains are bioprocess compatible. Analytical protein and glycan data are presented to demonstrate the capability of glycoengineered P. pastoris to produce fully humanized, active and immunologically compatible rhLF. In addition, the biological activity of the rhLF glycoforms produced was tested in vitro revealing the importance of N-acetylneuraminic (sialic) acid as a terminal sugar in propagation of proper immune responses.     

Expression of human CMP-N-acetylneuraminic acid synthetase and CMP-sialic acid transporter in tobacco suspension-cultured cell

Plant cells have no beta1,4-galactosylated and sialylated glycan, which plays important roles in biological functions in animal cells. Previously, we generated transgenic tobacco BY2 suspension-cultured cells that produced human beta1,4-galactosyltransferase [N.Q. Palacpac, S. Yoshida, H. Sakai, Y. Kimura, K. Fujiyama, T. Yoshida, T. Seki, Stable expression of human beta1,4-galactosyltransferase in plant cells modifies N-linked glycosylation pattern, Proc. Natl. Acad. Sci. USA 96 (1999) 4692-4697]. In this study, we introduced two critical genes encoding human CMP-N-acetylneuraminic acid synthetase and CMP-sialic acid transporter into tobacco suspension-cultured cell to pave a route for sialic biosynthetic pathway. The recombinant human proteins showed their biological activities. These results show that the plant cell can be a useful bioreactor for the production of mammalian glycoproteins.     

Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines

In the past decades, a large number of studies in mammalian cells have revealed that processing of glycoproteins is compartmentalized into several subcellular organelles that process N-glycans to generate complex-type oligosaccharides with terminal N -acetlyneuraminic acid. Recent studies also suggested that processing of N-glycans in insect cells appear to follow a similar initial pathway but diverge at subsequent processing steps. N-glycans from insect cell lines are not usually processed to terminally sialylated complex-type structures but are instead modified to paucimannosidic or oligomannose structures. These differences in processing between insect cells and mammalian cells are due to insufficient expression of multiple processing enzymes including glycosyltransferases responsible for generating complex-type structures and metabolic enzymes involved in generating appropriate sugar nucleotides. Recent genomics studies suggest that insects themselves may include many of these complex transferases and metabolic enzymes at certain developmental stages but expression is lost or limited in most lines derived for cell culture. In addition, insect cells include an N -acetylglucosaminidase that removes a terminal N -acetylglucosamine from the N-glycan. The innermost N -acetylglucosamine residue attached to asparagine residue is also modified with alpha(1,3)-linked fucose, a potential allergenic epitope, in some insect cells. In spite of these limitations in N-glycosylation, insect cells have been widely used to express various recombinant proteins with the baculovirus expression vector system, taking advantage of their safety, ease of use, and high productivity. Recently, genetic engineering techniques have been applied successfully to insect cells in order to enable them to produce glycoproteins which include complex-type N-glycans. Modifications to insect N-glycan processing include the expression of missing glycosyltransferases and inclusion of the metabolic enzymes responsible for generating the essential donor sugar nucleotide, CMP- N -acetylneuraminic acid, required for sialylation. Inhibition of N -acetylglucosaminidase has also been applied to alter N-glycan processing in insect cells. This review summarizes current knowledge on N-glycan processing in lepidopteran insect cell lines, and recent progress in glycoengineering lepidopteran insect cells to produce glycoproteins containing complex N-glycans.     

Evidence for a sialic acid salvaging pathway in lepidopteran insect cells

We previously described a transgenic insect cell line, Sfbeta4GalT/ST6, that expresses mammalian beta-1,4-galactosyltransferase and alpha2,6-sialyltransferase genes and produces glycoproteins with terminally sialylated N-glycans. The ability of these cells to produce sialylated N-glycans was surprising because insect cells contain only small amounts of sialic acid and no detectable CMP-sialic acid. Thus, it was of interest to investigate potential sources of sialic acids for sialoglycoprotein synthesis by these cells. We found that Sfbeta4GalT/ST6 cells can produce sialylated N-glycans when cultured in the presence but not in the absence of fetal bovine serum. The serum component(s) supporting N-glycan sialylation by Sfbeta4GalT/ST6 cells is relatively large-it was not removed by dialysis in a 50,000-molecular-weight cutoff membrane. Serum-free media supplemented with purified fetuin but not asialofetuin supported N-glycan sialylation by Sfbeta4GalT/ST6 cells. The terminally sialylated N-glycans isolated from fetuin also supported glycoprotein sialylation by Sfbeta4GalT/ST6 cells. Finally, serum-free medium supplemented with N-acetylneuraminic acid or N-acetylmannosamine supported glycoprotein sialylation by Sfbeta4GalT/ST6 cells but to a much lower degree than serum or fetuin. These results provide the first evidence of a sialic acid salvaging pathway in insect cells, which begins to explain how Sfbeta4GalT/ST6 and other transgenic insect cell lines can sialylate recombinant glycoproteins in the absence of a more obvious source of CMP-sialic acid.     

A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins

We have previously engineered transgenic insect cell lines to express mammalian glycosyltransferases and showed that these cells can sialylate N-glycoproteins, despite the fact that they have little intracellular sialic acid and no detectable CMP-sialic acid. In the accompanying study, we presented evidence that these cell lines can salvage sialic acids for de novo glycoprotein sialylation from extracellular sialoglycoproteins, such as fetuin, found in fetal bovine serum. This finding led us to create a new transgenic insect cell line designed to synthesize its own sialic acid and CMP-sialic acid. SfSWT-1 cells, which encode five mammalian glycosyltransferases, were transformed with two additional mammalian genes that encode sialic acid synthase and CMP-sialic acid synthetase. The resulting cell line expressed all seven mammalian genes, produced CMP-sialic acid, and sialylated a recombinant glycoprotein when cultured in a serum-free growth medium supplemented with N-acetylmannosamine. Thus the addition of mammalian genes encoding two enzymes involved in CMP-sialic acid biosynthesis yielded a new transgenic insect cell line, SfSWT-3, that can sialylate recombinant glycoproteins in the absence of fetal bovine serum. This new cell line will be widely useful as an improved host for baculovirus-mediated recombinant glycoprotein production.     

Improvement of glycosylation in insect cells with mammalian glycosyltransferases

The N-glycans of recombinant glycoproteins expressed in insect cells mainly contain high mannose or tri-mannose structures, which are truncated forms of the sialylated N-glycans found in mammalian cells. Because asialylated glycoproteins have a shorter half-life in blood circulation, we investigated if sialylated therapeutic glycoprotein can be produced from insect cells by enhancing the N-glycosylation machinery of the cells. We co-expressed in two insect cell lines, Sf9 and Ea4, the human alpha1-antitrypsin (halpha1AT) protein with a series of key glycosyltransferases, including GlcNAc transferase II (GnT2), beta1,4-galactosyltransferase (beta14GT), and alpha2,6-sialyltransferase (alpha26ST) by a single recombinant baculovirus. We demonstrated that the enhancement of N-glycosylation is cell type-dependent and is more efficient in Ea4 than Sf9 cells. Glycan analysis indicated that sialylated halpha1AT proteins were produced in Ea4 insect cells expressing the above-mentioned exogenous glycosyltransferases. Therefore, our expression strategy may simplify the production of humanized therapeutic glycoproteins by improving the N-glycosylation pathway in specific insect cells, with an ensemble of exogenous glycosyltransferases in a single recombinant baculovirus.     

酵母表达人源化糖蛋白研究进展

与人体天然复杂型糖蛋白相比,使用酵母生产的药用蛋白带有高甘露糖型N-糖链。这一差异在临床应用中产生了许多不良影响。目前,可以通过消除酵母特有的内源糖基化反应,引入哺乳动物细胞中的一系列糖基转移酶及转运蛋白对酵母糖基化路径进行改造,从而使其表达出人源化的复杂型N-聚糖。本文介绍了酵母N-糖基化特点、糖基化不均一性,综述了近年来利用基因工程改造酵母N-糖基化路径获得特定的人源N-连接糖蛋白以及使用内切糖苷酶生产人源糖蛋白的研究进展,并且对存在的问题及今后的发展前景进行了讨论。     

N-glycosylation sites of plant purple acid phosphatases important for protein expression and secretion in insect cells

Analysis of plant purple acid phosphatases (PAPs) showed high conservation and different distribution of N-glycosylation sites. Oligosaccharide structures of Lupinus luteus acid phosphatase (Lu_AP) produced in insect cells were determined. Mutant Lu_AP and Phaseolus vulgaris (Ph_AP) phosphatases lacking possibility of N-glycosylation at highly conserved sites were generated and expressed in insect cells. A role for N-glycosylation in the stability of PAPs was indicated by unsuccessful attempts to secrete Ph_AP and Lu_AP mutants generated by replacing Asn residues of conserved glycosylation sequons by Ser residues either singly or in combination. We showed that Ph_AP belongs to the group of glycoproteins that require occupancy of all highly conserved glycosylation sites for secretion, whereas replacing of the third position of the glycosylation sequon indicated that Lu_AP may tolerate the absence of some N-glycans. However, the N-glycan located at the polypeptide C-terminus was crucial for secretion of both enzymes. PAP specific activity of glycosylation mutants successfully secreted was similar to the wild-type recombinant proteins.